FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 340:392-393 February 4, 1999 Number 5 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article PubMed Citation

To the Editor: Indinavir, a human immunodeficiency virus (HIV)–protease inhibitor, improves survival in HIV-infected patients. Although urolithiasis and renal dysfunction are associated with short-term use of indinavir,^1,2 no adverse effects have been reported in patients receiving long-term indinavir therapy. We describe two men with hemophilia in whom renal atrophy developed during long-term treatment with indinavir.

The first patient was a 31-year-old, HIV-infected man with hemophilia who received treatment with zalcitabine (dideoxycytidine, 2.25 mg per day) and indinavir (2400 mg orally three times a day). The plasma HIV RNA level fell from 100,000 to less than 400 copies per milliliter; the . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Herman, J. S., Ives, N. J., Nelson, M., Gazzard, B. G., Easterbrook, P. J. (2001). Incidence and risk factors for the development of indinavir-associated renal complications. J Antimicrob Chemother 48: 355-360 [Abstract] [Full Text]